An oncology acquisition anchored the health and biotech session, as Thalia Therapeutics (AIM:THAT) moved to add a clinical-stage RNA therapy to its pipeline through an oversubscribed fundraise. Away from the deal, Primary Health Properties advanced joint venture talks, Verici Dx completed its US regulatory footprint, and two further companies reported results and funding plans.
Thalia Therapeutics acquires AML RNA therapy firm in oversubscribed raise
Thalia Therapeutics (AIM:THAT) is acquiring oncology company Sanmirna Therapeutics, adding the clinical-stage RNA therapy miRisten to its pipeline in a deal funded by a £2.75m placing at 0.6p per share that was oversubscribed. MiRisten is targeted at acute myeloid leukaemia, extending Thalia's reach into RNA-based cancer treatment. The shares rose 17.4% to 0.675p on the news.
Primary Health Properties in advanced joint venture talks for private hospital portfolio
Primary Health Properties (LSE:PHP) confirmed it is in advanced discussions with an unnamed investor to establish a new joint venture seeded with its private hospital portfolio. The structure would allow PHP to recycle capital while retaining exposure to the asset class through a partnership arrangement. The shares gained 4.1% to 95.6p as investors welcomed the potential transaction.
Verici Dx secures New York approval to complete US nationwide coverage
Verici Dx (AIM:VRCI) obtained New York State laboratory certification for its Tutivia kidney transplant rejection test, completing authorisation across all 50 US states. New York had been the final regulatory hurdle for nationwide commercial availability, given the state's separate and more stringent laboratory licensing requirements. The shares were unchanged at 0.375p. The milestone positions Tutivia for unrestricted US commercial deployment without geographic carve-outs.
Beximco Pharma half-year profit surges 36% on domestic and export growth
Beximco Pharmaceuticals (AIM:BXP) reported profit after tax growth of more than a third in the six months to December 2025, with both its Bangladesh home market and international export business contributing to the acceleration. Revenue growth trailed the profit expansion, pointing to improved operating leverage across the group's generic pharmaceuticals operations. The shares were quoted at 42.5p.
Cambridge Cognition raises minimum £2.5m for regulatory clearances and platform upgrades
Cambridge Cognition Holdings (AIM:COG) launched a fundraise targeting a minimum of £2.5m to finance CE marking and FDA clearance for its digital cognitive assessment platform, alongside paediatric data development and speech recognition enhancements. The capital raise is intended to broaden the addressable market for its technology across both European and US regulated healthcare pathways. The shares slipped 4.0% to 33.1p on the announcement.
